Osimertinib‐induced severe interstitial lung disease: A case report

Lung cancer is globally one of the leading causes of malignant tumor‐related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Mengdi, Mo, Ting, Shen, Lulei, Yang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610285/
https://www.ncbi.nlm.nih.gov/pubmed/31241220
http://dx.doi.org/10.1111/1759-7714.13127
_version_ 1783432477359996928
author Fan, Mengdi
Mo, Ting
Shen, Lulei
Yang, Li
author_facet Fan, Mengdi
Mo, Ting
Shen, Lulei
Yang, Li
author_sort Fan, Mengdi
collection PubMed
description Lung cancer is globally one of the leading causes of malignant tumor‐related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78‐year‐old man that was treated and responded favorably with Osimertinib after the failure of other therapies. Unfortunately, the patient developed severe interstitial lung disease during the treatment procedure.
format Online
Article
Text
id pubmed-6610285
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-66102852019-07-16 Osimertinib‐induced severe interstitial lung disease: A case report Fan, Mengdi Mo, Ting Shen, Lulei Yang, Li Thorac Cancer Case Reports Lung cancer is globally one of the leading causes of malignant tumor‐related mortality and ranks as having the highest incidence found in men and second in women. Osimertinib is a drug used to target lung cancer but its toxicity is not fully understood. Here we present a case of lung adenocarcinoma in a 78‐year‐old man that was treated and responded favorably with Osimertinib after the failure of other therapies. Unfortunately, the patient developed severe interstitial lung disease during the treatment procedure. John Wiley & Sons Australia, Ltd 2019-06-26 2019-07 /pmc/articles/PMC6610285/ /pubmed/31241220 http://dx.doi.org/10.1111/1759-7714.13127 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Fan, Mengdi
Mo, Ting
Shen, Lulei
Yang, Li
Osimertinib‐induced severe interstitial lung disease: A case report
title Osimertinib‐induced severe interstitial lung disease: A case report
title_full Osimertinib‐induced severe interstitial lung disease: A case report
title_fullStr Osimertinib‐induced severe interstitial lung disease: A case report
title_full_unstemmed Osimertinib‐induced severe interstitial lung disease: A case report
title_short Osimertinib‐induced severe interstitial lung disease: A case report
title_sort osimertinib‐induced severe interstitial lung disease: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610285/
https://www.ncbi.nlm.nih.gov/pubmed/31241220
http://dx.doi.org/10.1111/1759-7714.13127
work_keys_str_mv AT fanmengdi osimertinibinducedsevereinterstitiallungdiseaseacasereport
AT moting osimertinibinducedsevereinterstitiallungdiseaseacasereport
AT shenlulei osimertinibinducedsevereinterstitiallungdiseaseacasereport
AT yangli osimertinibinducedsevereinterstitiallungdiseaseacasereport

Ejemplares similares